Erdemoglu, AKOzbakir, S2020-06-252020-06-252000closedAccess0001-63141600-0404https://hdl.handle.net/20.500.12587/2834Objective - The efficacy and safety of valproic acid were assessed as a prophylactic agent in migraine patients who previously derived no significant benefit from conventional prophylactic medications for migraine. Patients and methods - One hundred and twenty patients aged 23-58 years with the diagnosis of migraine without aura. Response to therapy was determined by using a headache calendar detailing the frequency and severity of attacks. Reduction of 50% or greater in the frequency or severity of headache was considered as improvement. Results - Improvement was observed in headache frequency within 67% of patients. Headache severity had been improved in 60% of patients. The mean average dosage of valproic acid was 1250 mg daily. Most of the side effects are mild and tolerable. Conclusion - These results suggest that valproic acid is effective and safe in the treatment of refractory migraine headache.eninfo:eu-repo/semantics/closedAccessvalproic acidmigrainerefractory headachetreatmentprophylaxisArticle10263543582-s2.0-003371267311125749Q1WOS:000165593800004Q2